TMDX (TransMedics Group) Research & Development: $76.8 Mil (TTM As of Mar. 2026)


TMDX TransMedics Group Inc TMDX
69 GF Score
Price $77.75
GF Value $166.22
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is TransMedics Group Research & Development?

TransMedics Group TMDX +0.17% 69 Research & Development is $76.8 Mil as of Mar. 2026. GuruFocus rates TMDX with a GF Score™ of 69/100 and a GF Value™ of $166.22 (Possible Value Trap). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. TransMedics Group's Research & Development for the three months ended in Mar. 2026 was $24.9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $76.8 Mil.

TransMedics Group  (NAS:TMDX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TransMedics Group Research & Development Related Terms

TransMedics Group Research & Development Historical Data

* Premium members only.

The historical data trend for TransMedics Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransMedics Group Research & Development Chart

TransMedics Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.30 26.81 63.27 55.97 69.06

TransMedics Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.16 15.93 15.26 20.70 24.88
TMDX
69GF Score
TransMedics Group Inc TMDX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransMedics Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $76.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $76.8 Mil mean?
TransMedics Group (TMDX) has a Research & Development of $76.8 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on TransMedics Group and its competitors.
Is TransMedics Group's Research & Development too high?
TransMedics Group's current Research & Development is $76.8 Mil. Overall, TransMedics Group has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's Research & Development compare to AXGN and ESTA?
TransMedics Group's Research & Development of $76.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on TransMedics Group and its competitors. TransMedics Group's current Research & Development is $76.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
Based on GuruFocus' analysis, TransMedics Group (TMDX) is currently considered Possible Value Trap. The stock's GF Value™ is $166.22, compared to a current price of $77.75 — trading 53.2% below its estimated fair value. The current Research & Development is $76.8 Mil. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For TransMedics Group (TMDX), the current Research & Development is $76.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TransMedics Group (TMDX) Overvalued in 2026?

Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued. The current stock price of $77.75 is trading 53.2% below its estimated GF Value™ of $166.22. GuruFocus considers TransMedics Group to be Possible Value Trap.

Key valuation signals for TMDX:

  • Research & Development: $76.8 Mil
  • GF Value™: $166.22 vs. price of $77.75 (53.2% below fair value)
  • GF Score™: 69/100 with 9 warning signs

No single metric tells the full story. See the TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TransMedics Group Business Description

Address 200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score

Get the complete analysis for TMDX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$77.75
Price
$166.22
GF Value